ILF/CIPHER PADO/IATT Update for ARV Manufacturers

19 October 2015 | Conference call (By invitation only)

As part of the thematic roundtable series on paediatric ARVs, the ILF and CIPHER invited both generic and originator ARV manufacturers for a webinar focusing on some of the recent progress in the paediatric ARV space. The Paediatric ARV Drug Optimization (PADO) working group and the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children (IATT) took this opportunity to provide updates on the revision of the WHO 2013 Consolidated ARV Guidelines and the IATT Optimal List of Paediatric ARV Formulations. ARV manufacturers were able to stay up-to-date with this moving field and ask questions to members of these two working groups. For additional background information, please refer to the latest ILF/CIPHER Thematic Roundtable on Paediatric ARVs meeting report.



Meeting material

  • Related documents
  • Presentations

Opening words
Sébastien Morin, International AIDS Society, Switzerland - Research Officer, ILF

Presentation

Presentation I – PADO: Background and update
Martina Penazzato, WHO, Switzerland

Presentation II – IATT Optimal List of Paediatric ARV Formulations: Background and update
Nandita Sugandhi, CHAI, United States

Presentation

Q&A
Moderated by Nandita Sugandhi, CHAI, United States

Presentation

Closing
Sébastien Morin , International AIDS Society, Switzerland - Research Officer, ILF

Presentation